MedTrace Logo

IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab

NCT03340610 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-05-24

Study results available
· View outcomes & findings →

Summary

This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be enrolled.

Conditions

Interventions

DRUG

Alflibercept

Intravitreal Injection

Sponsors & Collaborators

  • Southeast Retina Center, Georgia

    lead OTHER

Principal Investigators

  • Dennis M Marcus, MD · Southeast Retina Center, PC.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2018-12-31
Completion
2018-12-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03340610 on ClinicalTrials.gov